Fig. 1

Nc886 TSS200 methylation status and its correlation with clinical parameters of PrCa in patients of the TCGA-PRAD cohort. a Average TSS200 methylation of nc886 in matched normal and tumor prostate tissue of 50 patients from TCGA cohort and 52 patients from STANFORD cohort data available in GSE76938 GEO dataset. b Average TSS200 methylation of nc886 for normal and metastatic prostate tissue data available in GSE38240 GEO dataset. In A and B the numbers below the boxes indicate the mean value of each distribution. c Average TSS200 methylation of nc886 in association with Gleason Score of tumor tissue of 329 patients. d Association between average TSS200 methylation of nc886 and clinical T values of tumor tissue of 272 patients. e Association between average TSS200 methylation of nc886 and biochemical recurrence in 276 patients. Clinical data analyses incorporate TCGA-PRAD DNA methylation data of the tissues with available associated Gleason score data (c), Clinical T-value data (d) and Biochemical recurrence data (e). Two-tailed T test was performed for all categories, and only significant differences are depicted: * P value < 0.05; ** P-value < 0.01; *** P -value < 0.001; **** P-value < 0.0001